Traditional Chinese medicine in the prevention and treatment of cancer and cancer metastasis (Review)

Ye,Lin; Jia,Yongning; Ji,Ke; Sanders,Andrew J.; Xue,Kan; Ji,Jiafu; Mason,Malcolm  D.; Jiang,Wen  G.

doi:10.3892/ol.2015.3459

Traditional Chinese medicine in the prevention and treatment of cancer and cancer metastasis (Review)

Authors:
- Lin Ye
- Yongning Jia
- Ke Ji
- Andrew J. Sanders
- Kan Xue
- Jiafu Ji
- Malcolm D. Mason
- Wen G. Jiang
View Affiliations

Affiliations: Cardiff University‑Peking University Cancer Institute, Cardiff University School of Medicine, Cardiff CF14 4XN, UK, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Surgery, Peking University Cancer Hospital and Institute, Haidian, Beijing 100142, P.R. China, Institute of Cancer and Genetics, Cardiff University School of Medicine, Cardiff CF14 4XN, UK
Published online on: July 6, 2015 https://doi.org/10.3892/ol.2015.3459
Pages: 1240-1250

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Traditional Chinese medicine (TCM) has been a major part of healthcare in China, and has extensively affected medicine and healthcare in surrounding countries over a long period of time. In the fight against cancer, certain anticancer remedies using herbs or herbal formulas derived from TCM have been developed for the management of malignancies. Furthermore, there are clinical trials registered for the use of herbal remedies in cancer management. Herbal medicine has been used as part of combined therapies to reduce the side‑effects of chemotherapy, including bone marrow suppression, nausea and vomiting. Herbal remedies have also been used as chemopreventive therapies to treat precancerous conditions in order to reduce the incidence of cancer in high‑risk populations. Emerging evidence has revealed that herbal remedies can regulate the proliferation, apoptosis, adhesion and migration of cancer cells. In addition to this direct effect upon cancer cells, a number of herbal remedies have been identified to suppress angiogenesis and therefore reduce tumour growth. The inhibition of tumour growth may also be due to modifications of the host immune system by the herbal treatment. However, the precise mechanisms underlying the therapeutic effects of herbal remedies remain poorly understood and are yet to be fully elucidated. The present study aims to summarize the current literature and clinical trial results of herbal remedies for cancer treatment, with a particular focus on the recent findings and development of the Yangzheng Xiaoji capsule.

View Figures

View References

1	Nahin RL, Barnes PM, Stussman BJ and Bloom B: Costs of complementary and alternative medicine (CAM) and frequency of visits to CAM practitioners: United States, 2007. Natl Health Stat Report. 1–14. 2009.PubMed/NCBI
2	Klempner SJ and Bubley G: Complementary and alternative medicines in prostate cancer: from bench to bedside? Oncologist. 17:830–837. 2012. View Article : Google Scholar : PubMed/NCBI
3	Grayson M: Traditional Asian Medicine. Nature. 480:S812011. View Article : Google Scholar : PubMed/NCBI
4	Chen GQ, Zhu J, Shi XG, et al: In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood. 88:1052–1061. 1996.PubMed/NCBI
5	Cai XZ: Observation of therapeutic effect of single-dose combined administration of Qinghaosu, sulphomethoxine, pyrimethamine and primaquine in the treatment of chloroquine-resistant malignant malaria (author's transl). Zhonghua Nei Ke Za Zhi. 20:724–727. 1981.(In Chinese). PubMed/NCBI
6	Kang SH, Jeong SJ, Kim SH, et al: Icariside II induces apoptosis in U937 acute myeloid leukemia cells: role of inactivation of STAT3-related signaling. PLoS One. 7:e287062012. View Article : Google Scholar : PubMed/NCBI
7	He R, Mott BT, Rosenthal AS, Genna DT, Posner GH and Arav-Boger R: An artemisinin-derived dimer has highly potent anti-cytomegalovirus (CMV) and anti-cancer activities. PLoS One. 6:e243342011. View Article : Google Scholar : PubMed/NCBI
8	Firestone GL and Sundar SN: Anticancer activities of artemisinin and its bioactive derivatives. Expert Rev Mol Med. 11:e322009. View Article : Google Scholar : PubMed/NCBI
9	Lai H, Nakase I, Lacoste E, Singh NP and Sasaki T: Artemisinin-transferrin conjugate retards growth of breast tumors in the rat. Anticancer Res. 29:3807–3810. 2009.PubMed/NCBI
10	Sun WC, Han JX, Yang WY, Deng DA and Yue XF: Antitumor activities of 4 derivatives of artemisic acid and artemisinin B in vitro. Zhongguo Yao Li Xue Bao. 13:541–543. 1992.(In Chinese). PubMed/NCBI
11	Zhang SY, Gu CH and Gao XD: A randomly double-blinded and multicentre study of chemotherapy assisted Yangzhengxiaoji capsule on treating primary hepatic carcinoma. J Diffic Compl Case. 8:461–464. 2009.
12	Jiang WG, Ye L, Ji K, et al: Antitumour effects of Yangzheng Xiaoji in human osteosarcoma: the pivotal role of focal adhesion kinase signalling. Oncol Rep. 30:1405–1413. 2013.PubMed/NCBI
13	Ye L, Ji K, Frewer N, Ji J and Jiang WG: Impact of Yangzheng Xiaoji on the adhesion and migration of human cancer cells: the role of the AKT signalling pathway. Anticancer Res. 32:2537–2543. 2012.PubMed/NCBI
14	Jiang WG, Ye L, Ji K, Frewer N, Ji J and Mason MD: Inhibitory effects of Yangzheng Xiaoji on angiogenesis and the role of the focal adhesion kinase pathway. Int J Oncol. 41:1635–1642. 2012.PubMed/NCBI
15	Konkimalla VB and Efferth T: Evidence-based Chinese medicine for cancer therapy. J Ethnopharmacol. 116:207–210. 2008. View Article : Google Scholar : PubMed/NCBI
16	No authors listed. Astragalus membranaceus. Monograph. Altern Med Rev. 8:72–77. 2003.PubMed/NCBI
17	Hofseth LJ and Wargovich MJ: Inflammation, cancer, and targets of ginseng. J Nutr. 137 (Suppl 1):183S–185S. 2007.PubMed/NCBI
18	Wang GS: Medical uses of Mylabris in ancient China and recent studies. J Ethnopharmacol. 26:147–162. 1989. View Article : Google Scholar : PubMed/NCBI
19	Lu CX, Nan KJ and Lei Y: Agents from amphibians with anticancer properties. Anticancer Drugs. 19:931–939. 2008. View Article : Google Scholar : PubMed/NCBI
20	Shukla Y and Kalra N: Cancer chemoprevention with garlic and its constituents. Cancer Lett. 247:167–181. 2007. View Article : Google Scholar : PubMed/NCBI
21	Kuttan R, Bhanumathy P, Nirmala K and George MC: Potential anticancer activity of turmeric (Curcuma longa). Cancer Lett. 29:197–202. 1985. View Article : Google Scholar : PubMed/NCBI
22	Wang GS: Medical uses of mylabris in ancient China and recent studies. J Ethnopharmacol. 26:147–162. 1989. View Article : Google Scholar : PubMed/NCBI
23	Lee TK, Johnke RM, Allison RR, O'Brien KF and Dobbs LJ Jr: Radioprotective potential of ginseng. Mutagenesis. 20:237–243. 2005. View Article : Google Scholar : PubMed/NCBI
24	Liu D and Chen Z: The effects of cantharidin and cantharidin derivates on tumour cells. Anticancer Agents Med Chem. 9:392–396. 2009. View Article : Google Scholar : PubMed/NCBI
25	Yoshida Y, Wang MQ, Liu JN, Shan BE and Yamashita U: Immunomodulating activity of Chinese medicinal herbs and Oldenlandia diffusa in particular. Int J Immunopharmacol. 19:359–370. 1997. View Article : Google Scholar : PubMed/NCBI
26	Wang Y, Qian XJ, Hadley HR and Lau BH: Phytochemicals potentiate interleukin-2 generated lymphokine-activated killer cell cytotoxicity against murine renal cell carcinoma. Mol Biother. 4:143–146. 1992.PubMed/NCBI
27	Liu J, Shi Z, Xu Z, et al: Clinical observation on treatment of non-parvicellular carcinoma of the lung with jin fu kang oral liquid. J Tradit Chin Med. 20:96–100. 2000.PubMed/NCBI
28	McCulloch M, See C, Shu XJ, et al: Astragalus-based Chinese herbs and platinum-based chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials. J Clin Oncol. 24:419–430. 2006. View Article : Google Scholar : PubMed/NCBI
29	Yun TK and Choi SY: Preventive effect of ginseng intake against various human cancers: a case-control study on 1987 pairs. Cancer Epidemiol Biomarkers Prev. 4:401–408. 1995.PubMed/NCBI
30	Wu P, Dugoua JJ, Eyawo O and Mills EJ: Traditional Chinese Medicines in the treatment of hepatocellular cancers: a systematic review and meta-analysis. J Exp Clin Cancer Res. 28:1122009. View Article : Google Scholar : PubMed/NCBI
31	Chen M, May BH, Zhou IW, Xue CC and Zhang AL: FOLFOX 4 combined with herbal medicine for advanced colorectal cancer: a systematic review. Phytother Res. 28:976–991. 2014. View Article : Google Scholar : PubMed/NCBI
32	Wang Z, Wen J, Zhang J, Ye M and Guo D: Simultaneous determination of four bufadienolides in human liver by high-performance liquid chromatography. Biomed Chromatogr. 18:318–322. 2004. View Article : Google Scholar : PubMed/NCBI
33	Wang J, Jin Y, Xu Z, Zheng Z and Wan S: Involvement of caspase-3 activity and survivin downregulation in cinobufocini-induced apoptosis in A 549 cells. Exp Biol Med (Maywood). 234:566–572. 2009. View Article : Google Scholar : PubMed/NCBI
34	Wang DL, Qi FH, Xu HL, et al: Apoptosis-inducing activity of compounds screened and characterized from cinobufacini by bioassay-guided isolation. Mol Med Rep. 3:717–722. 2010.PubMed/NCBI
35	Qi FH, Li AY, Lv H, et al: Apoptosis-inducing effect of cinobufacini, Bufo bufo gargarizans Cantor skin extract, on human hepatoma cell line BEL-7402. Drug Discov Ther. 2:339–343. 2008.PubMed/NCBI
36	Qi F, Li A, Zhao L, et al: Cinobufacini, an aqueous extract from Bufo bufo gargarizans Cantor, induces apoptosis through a mitochondria-mediated pathway in human hepatocellular carcinoma cells. J Ethnopharmacol. 128:654–661. 2010. View Article : Google Scholar : PubMed/NCBI
37	Cui X, Inagaki Y, Xu H, et al: Anti-hepatitis B virus activities of cinobufacini and its active components bufalin and cinobufagin in HepG2.2.15 cells. Biol Pharm Bull. 33:1728–1732. 2010. View Article : Google Scholar : PubMed/NCBI
38	Meng Z, Yang P, Shen Y, et al: Pilot study of Huachansu in patients with hepatocellular carcinoma, non-small cell lung cancer, or pancreatic cancer. Cancer. 115:5309–5318. 2009. View Article : Google Scholar : PubMed/NCBI
39	Qin TJ, Zhao XH, Yun J, Zhang LX, Ruan ZP and Pan BR: Efficacy and safety of gemcitabine-oxaliplatin combined with huachansu in patients with advanced gallbladder carcinoma. World J Gastroenterol. 14:5210–5216. 2008. View Article : Google Scholar : PubMed/NCBI
40	Xie X, Huang X, Li J, et al: Efficacy and safety of Huachansu combined with chemotherapy in advanced gastric cancer: a meta-analysis. Med Hypotheses. 81:243–250. 2013. View Article : Google Scholar : PubMed/NCBI
41	Dong J, Su SY, Wang MY and Zhan Z: Shenqi fuzheng, an injection concocted from Chinese medicinal herbs, combined with platinum-based chemotherapy for advanced non-small cell lung cancer: a systematic review. J Exp Clin Cancer Res. 29:1372010. View Article : Google Scholar : PubMed/NCBI
42	Dai Z, Wan X, Kang H, et al: Clinical effects of shenqi fuzheng injection in the neoadjuvant chemotherapy for local advanced breast cancer and the effects on T-lymphocyte subsets. J Tradit Chin Med. 28:34–38. 2008. View Article : Google Scholar : PubMed/NCBI
43	Yang AK, He SM, Liu L, Liu JP, Wei MQ and Zhou SF: Herbal interactions with anticancer drugs: mechanistic and clinical considerations. Cur Med Chem. 17:1635–1678. 2010. View Article : Google Scholar
44	Lu Y, Wu LQ, Dong Q and Li CS: Experimental study on the effect of Kang-Lai-Te induced apoptosis of human hepatoma carcinoma cell HepG2. Hepatobiliary Pancreat Dis Int. 8:267–272. 2009.PubMed/NCBI
45	Guo HY, Cai Y, Yang XM, et al: Randomized phase II trial on mitomycin-C/cisplatin +/- KLT in heavily pretreated advanced breast cancer. Am J Chin Med. 36:665–674. 2008. View Article : Google Scholar : PubMed/NCBI
46	Liu X, Xu F, Wang G, Diao X and Li Y: Kanglaite injection plus chemotherapy versus chemotherapy alone for non-small cell lung cancer patients: A systematic review and meta-analysis. Curr Ther Res Clin Exp. 69:381–411. 2008. View Article : Google Scholar : PubMed/NCBI
47	Wang QL, Xue CM, Wu SP, Li YX and Bi XJ: Clinical observation on Yangzhengxiaoji capsule in treatment of 60 cases of moderate to severe degree atypical proliferation of gastric mucosa. Chin J Diffic Compl Case. 7:38–39. 2008.(In Chinese).
48	Xue K, Shan F and Ji J: Meta-analysis of the safety of Yangzhengxiaoji capsule for the treatment of cancer and precancerosis. Chin J Clin Oncol. 40:1318–1323. 2013.
49	Chinese Pharmacopoeia Commission, . Pharmacopoeia of the People's Republic of China 20101. 9th. Chemical Industry Press; Beijing: 2011
50	Li T, Tamada K, Abe K, et al: The restoration of the antitumor T cell response from stress-induced suppression using a traditional Chinese herbal medicine Hochu-ekki-to (TJ-41: Bu-Zhong-Yi-Qi-Tang). Immunopharmacology. 43:11–21. 1999. View Article : Google Scholar : PubMed/NCBI
51	Niwa K, Hashimoto M, Morishita S, et al: Preventive effects of Juzen-taiho-to on N-methyl-N-nitrosourea and estradiol-17beta-induced endometrial carcinogenesis in mice. Carcinogenesis. 22:587–591. 2001. View Article : Google Scholar : PubMed/NCBI
52	Kamiyama H, Takano S, Ishikawa E, Tsuboi K and Matsumura A: Anti-angiogenic and immunomodulatory effect of the herbal medicine ‘Juzen-taiho-to’ on malignant glioma. Biol Pharm Bull. 28:2111–2116. 2005. View Article : Google Scholar : PubMed/NCBI
53	Saiki I: A Kampo medicine ‘Juzen-taiho-to’ - prevention of malignant progression and metastasis of tumor cells and the mechanism of action. Biol Pharm Bull. 23:677–688. 2000. View Article : Google Scholar : PubMed/NCBI
54	Ohnishi Y, Fujii H, Hayakawa Y, et al: Oral administration of a Kampo (Japanese herbal) medicine Juzen-taiho-to inhibits liver metastasis of colon 26-L5 carcinoma cells. Jpn J Cancer Res. 89:206–213. 1998. View Article : Google Scholar : PubMed/NCBI
55	Matsumoto M, Seya T, Kikkawa S, et al: Interferon gamma-producing ability in blood lymphocytes of patients with lung cancer through activation of the innate immune system by BCG cell wall skeleton. Int Immunopharmacol. 1:1559–1569. 2001. View Article : Google Scholar : PubMed/NCBI
56	Miyagami M and Katayama Y: Improvement of host-immunity by adjuvant therapy with juzen-taiho-to for patients with brain tumors. No Shinkei Geka. 31:401–409. 2003.(In Japanese). PubMed/NCBI
57	Ngo SN, Williams DB, Cobiac L and Head RJ: Does garlic reduce risk of colorectal cancer? A systematic review. J Nutr. 137:2264–2269. 2007.PubMed/NCBI
58	Sundaram SG and Milner JA: Diallyl disulfide inhibits the proliferation of human tumor cells in culture. Biochim Biophys Acta. 1315:15–20. 1996. View Article : Google Scholar : PubMed/NCBI
59	Nishino H, Iwashima A, Itakura Y, Matsuura H and Fuwa T: Antitumor-promoting activity of garlic extracts. Oncology. 46:277–280. 1989. View Article : Google Scholar : PubMed/NCBI
60	Arora A and Shukla Y: Induction of apoptosis by diallyl sulfide in DMBA-induced mouse skin tumors. Nutr Cancer. 44:89–94. 2002. View Article : Google Scholar : PubMed/NCBI
61	Arora A, Siddiqui IA and Shukla Y: Modulation of p53 in 7,12-dimethylbenz[a]anthracene-induced skin tumors by diallyl sulfide in Swiss albino mice. Mol Cancer Ther. 3:1459–1466. 2004.PubMed/NCBI
62	Kao ST, Yeh CC, Hsieh CC, et al: The Chinese medicine Bu-Zhong-Yi-Qi-Tang inhibited proliferation of hepatoma cell lines by inducing apoptosis via G0/G1 arrest. Life Sci. 69:1485–1496. 2001. View Article : Google Scholar : PubMed/NCBI
63	Zhu K, Fukasawa I, Furuno M, et al: Inhibitory effects of herbal drugs on the growth of human ovarian cancer cell lines through the induction of apoptosis. Gynecol Oncol. 97:405–409. 2005. View Article : Google Scholar : PubMed/NCBI
64	Okita K, Li Q, Murakamio T and Takahashi M: Anti-growth effects with components of Sho-saiko-to (TJ-9) on cultured human hepatoma cells. Eur J Cancer Prev. 2:169–175. 1993. View Article : Google Scholar : PubMed/NCBI
65	Chang WH, Chen CH and Lu FJ: Different effects of baicalein, baicalin and wogonin on mitochondrial function, glutathione content and cell cycle progression in human hepatoma cell lines. Planta Med. 68:128–132. 2002. View Article : Google Scholar : PubMed/NCBI
66	Chang WH, Chen CH, Gau RJ, et al: Effect of baicalein on apoptosis of the human Hep G2 cell line was induced by mitochondrial dysfunction. Planta Med. 68:302–306. 2002. View Article : Google Scholar : PubMed/NCBI
67	Motoo Y and Sawabu N: Antitumor effects of saikosaponins, baicalin and baicalein on human hepatoma cell lines. Cancer Lett. 86:91–95. 1994. View Article : Google Scholar : PubMed/NCBI
68	Matsuzaki Y, Kurokawa N, Terai S, Matsumura Y, Kobayashi N and Okita K: Cell death induced by baicalein in human hepatocellular carcinoma cell lines. Jpn J Cancer Res. 87:170–177. 1996. View Article : Google Scholar : PubMed/NCBI
69	Yano H, Mizoguchi A, Fukuda K, et al: The herbal medicine sho-saiko-to inhibits proliferation of cancer cell lines by inducing apoptosis and arrest at the G0/G1 phase. Cancer Res. 54:448–454. 1994.PubMed/NCBI
70	Xiao D, Herman-Antosiewicz A, Antosiewicz J, et al: Diallyl trisulfide-induced G(2)-M phase cell cycle arrest in human prostate cancer cells is caused by reactive oxygen species-dependent destruction and hyperphosphorylation of Cdc 25 C. Oncogene. 24:6256–6268. 2005. View Article : Google Scholar : PubMed/NCBI
71	Singh SV: Impact of garlic organosulfides on p21(H-ras) processing. J Nutr. 131:1046S–1048S. 2001.PubMed/NCBI
72	Bonness K, Aragon IV, Rutland B, Ofori-Acquah S, Dean NM and Honkanen RE: Cantharidin-induced mitotic arrest is associated with the formation of aberrant mitotic spindles and lagging chromosomes resulting, in part, from the suppression of PP2Aalpha. Mol Cancer Ther. 5:2727–2736. 2006. View Article : Google Scholar : PubMed/NCBI
73	Kohno T, Matsuda E, Sasaki H and Sasaki T: Protein-tyrosine kinase CAKbeta/PYK2 is activated by binding Ca2+/calmodulin to FERM F2 alpha2 helix and thus forming its dimer. Biochem J. 410:513–523. 2008. View Article : Google Scholar : PubMed/NCBI
74	Gilmore AP and Romer LH: Inhibition of focal adhesion kinase (FAK) signaling in focal adhesions decreases cell motility and proliferation. Mol Biol Cell. 7:1209–1224. 1996. View Article : Google Scholar : PubMed/NCBI
75	Cai J, Parr C, Watkins G, Jiang WG and Boulton M: Decreased pigment epithelium-derived factor expression in human breast cancer progression. Clin Cancer Res. 12:3510–3517. 2006. View Article : Google Scholar : PubMed/NCBI
76	Braren R, Hu H, Kim YH, Beggs HE, Reichardt LF and Wang R: Endothelial FAK is essential for vascular network stability, cell survival, and lamellipodial formation. J Cell Biol. 172:151–162. 2006. View Article : Google Scholar : PubMed/NCBI
77	Ochiai K, Takita S, Eiraku T, et al: Phosphodiesterase inhibitors. Part 3: Design, synthesis and structure-activity relationships of dual PDE3/4-inhibitory fused bicyclic heteroaromatic-dihydropyridazinones with anti-inflammatory and bronchodilatory activity. Bioorg Med Chem. 20:1644–1658. 2012. View Article : Google Scholar : PubMed/NCBI
78	Folkman J: Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov. 6:273–286. 2007. View Article : Google Scholar : PubMed/NCBI
79	Potente M, Gerhardt H and Carmeliet P: Basic and therapeutic aspects of angiogenesis. Cell. 146:873–887. 2011. View Article : Google Scholar : PubMed/NCBI
80	Ye B, Aponte M, Dai Y, et al: Ginkgo biloba and ovarian cancer prevention: epidemiological and biological evidence. Cancer Lett. 251:43–52. 2007. View Article : Google Scholar : PubMed/NCBI
81	Papadopoulos V, Kapsis A, Li H, et al: Drug-induced inhibition of the peripheral-type benzodiazepine receptor expression and cell proliferation in human breast cancer cells. Anticancer Res. 20:2835–2847. 2000.PubMed/NCBI
82	Chao JC and Chu CC: Effects of Ginkgo biloba extract on cell proliferation and cytotoxicity in human hepatocellular carcinoma cells. World J Gastroenterol. 10:37–41. 2004.PubMed/NCBI
83	Kim KS, Rhee KH, Yoon JH, Lee JG, Lee JH and Yoo JB: Ginkgo biloba extract (EGb 761) induces apoptosis by the activation of caspase-3 in oral cavity cancer cells. Oral Oncol. 41:383–389. 2005. View Article : Google Scholar : PubMed/NCBI
84	Koltermann A, Liebl J, Fürst R, Ammer H, Vollmar AM and Zahler S: Ginkgo biloba extract EGb 761 exerts anti-angiogenic effects via activation of tyrosine phosphatases. J Cell Mol Med. 13:2122–2130. 2009. View Article : Google Scholar : PubMed/NCBI
85	Tang PM, Chan JY, Zhang DM, et al: Pheophorbide a, an active component in Scutellaria barbata, reverses P-glycoprotein-mediated multidrug resistance on a human hepatoma cell line R-HepG2. Cancer Biol Ther. 6:504–509. 2007. View Article : Google Scholar : PubMed/NCBI
86	Goh D, Lee YH and Ong ES: Inhibitory effects of a chemically standardized extract from Scutellaria barbata in human colon cancer cell lines, LoVo. J Agric Food Chem. 53:8197–8204. 2005. View Article : Google Scholar : PubMed/NCBI
87	Yin X, Zhou J, Jie C, Xing D and Zhang Y: Anticancer activity and mechanism of Scutellaria barbata extract on human lung cancer cell line A549. Life Sci. 75:2233–2244. 2004. View Article : Google Scholar : PubMed/NCBI
88	Perez AT, Arun B, Tripathy D, et al: A phase 1B dose escalation trial of Scutellaria barbata (BZL101) for patients with metastatic breast cancer. Breast Cancer Res Treat. 120:111–118. 2010. View Article : Google Scholar : PubMed/NCBI
89	Dai ZJ, Lu WF, Gao J, et al: Anti-angiogenic effect of the total flavonoids in Scutellaria barbata D. Don. BMC Complement Altern Med. 13:1502013. View Article : Google Scholar : PubMed/NCBI
90	Shiau AL, Shen YT, Hsieh JL, Wu CL and Lee CH: Scutellaria barbata inhibits angiogenesis through downregulation of HIF-1 α in lung tumor. Environ Toxicol. 29:363–370. 2014. View Article : Google Scholar : PubMed/NCBI
91	Wei L, Lin J, Xu W, et al: Scutellaria barbata D. Don inhibits tumor angiogenesis via suppression of hedgehog pathway in a mouse model of colorectal cancer. Int J Mol Sci. 13:9419–9430. 2012. View Article : Google Scholar : PubMed/NCBI
92	Zhao D, Qin C, Fan X, Li Y and Gu B: Inhibitory effects of quercetin on angiogenesis in larval zebrafish and human umbilical vein endothelial cells. Eur J Pharmacol. 723:360–367. 2014. View Article : Google Scholar : PubMed/NCBI
93	Bellou S, Pentheroudakis G, Murphy C and Fotsis T: Anti-angiogenesis in cancer therapy: Hercules and hydra. Cancer Lett. 338:219–228. 2013. View Article : Google Scholar : PubMed/NCBI
94	Bosch FX and de Sanjosé S: The epidemiology of human papillomavirus infection and cervical cancer. Dis Markers. 23:213–227. 2007. View Article : Google Scholar : PubMed/NCBI
95	Zhang KH and Xie JF: Experimental study on the treatment of oral precancerous lesion - short and long term effect of tablet Anticancer II. Ann Acad Med Singapore. 18:528–532. 1989.PubMed/NCBI
96	Lu B, Xu L, Yu L and Zhang L: Extract of radix curcumae prevents gastric cancer in rats. Digestion. 77:87–91. 2008. View Article : Google Scholar : PubMed/NCBI
97	Volate SR, Davenport DM, Muga SJ and Wargovich MJ: Modulation of aberrant crypt foci and apoptosis by dietary herbal supplements (quercetin, curcumin, silymarin, ginseng and rutin). Carcinogenesis. 26:1450–1456. 2005. View Article : Google Scholar : PubMed/NCBI
98	Hou J, Lin PZ, Chen ZF, et al: Field population-based blocking treatment of esophageal epithelia dysplasia. World J Gastroenterol. 8:418–422. 2002.PubMed/NCBI
99	Ding Z, Gao F and Lin P: Long-term effect of treating patients with precancerous lesions of the esophagus. Zhonghua Zhong Liu Za Zhi. 21:275–277. 1999.(In Chinese). PubMed/NCBI
100	Sun Z, Guan X, Li N, Liu X and Chen X: Chemoprevention of oral cancer in animal models, and effect on leukoplakias in human patients with ZengShengPing, a mixture of medicinal herbs. Oral Oncol. 46:105–110. 2010. View Article : Google Scholar : PubMed/NCBI
101	Oh WK, Kantoff PW, Weinberg V, et al: Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer. J Clin Oncol. 22:3705–3712. 2004. View Article : Google Scholar : PubMed/NCBI
102	Olaku O, Zia F, Santana JM and White JD: The National Cancer Institute best case series program: a summary of cases of cancer patients treated with unconventional therapies in India. Integr Cancer Ther. 12:385–392. 2013. View Article : Google Scholar : PubMed/NCBI
103	Zia FZ and White JD: National Cancer Institute Best Case Series program. Integr Cancer Ther. 8:113–114. 2009. View Article : Google Scholar : PubMed/NCBI
104	Olaku O and White JD: Herbal therapy use by cancer patients: a literature review on case reports. Eur J Cancer. 47:508–514. 2011. View Article : Google Scholar : PubMed/NCBI